Analytical Data
-
Gene name
APOC3
- Application
-
Alternative Names
Apo-C3; APOCIII; APOC-III
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P02656
-
Expression Region
Ser21~Ala99
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein C-III (APOC3) is a crucial protein involved in lipid metabolism and plays a significant role in the regulation of triglyceride levels in plasma. Elevated levels of APOC3 are associated with increased risk of cardiovascular diseases and metabolic disorders, making it a key target for therapeutic interventions. Recent studies have highlighted its role in the inhibition of lipoprotein lipase (LPL), which is essential for the hydrolysis of triglycerides in lipoproteins. Furthermore, genetic variations in the APOC3 gene have been linked to altered lipid profiles and susceptibility to conditions such as hypertriglyceridemia. The reconstitution and characterization of APOC3 as a recombinant protein allow researchers to explore its structure-function relationships and interactions with other lipid transport proteins. This research not only enhances our understanding of lipid metabolism but also paves the way for the development of novel pharmacological strategies aimed at modulating APOC3 activity. By generating recombinant APOC3, scientists can investigate its biochemical properties and functional implications in detail, ultimately contributing to the design of therapies targeting dyslipidemia and associated metabolic disorders. Furthermore, understanding the mechanisms by which APOC3 affects lipid accumulation and clearance could provide insights into potential biomarkers for cardiovascular risk and guide personalized treatment approaches. The ongoing research in this field represents an essential endeavor in addressing the global burden of cardiovascular diseases and fostering advancements in lipid management.
